Mitomycin C-treated antigen-presenting cells as a tool for control of allograft rejection and autoimmunity: From bench to bedside

Human Immunology

Volumn 70, Issue 7, 2009, Pages 506-512

  Terness, Peter ^a   Kleist, Christian ^a   Simon, Helmut ^a   Sandra Petrescu, Flavius ^a   Ehser, Sandra ^a   Chuang, Jing Jing ^a   Mohr, Elisabeth ^a   Jiga, Lucian ^a   Greil, Johann ^a   Opelz, Gerhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allograft rejection; Autoimmunity; Multiple sclerosis; Suppressive antigen presenting cells; Tolerance induction

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GLUCOCORTICOID; LEUCINE ZIPPER PROTEIN; MITOMYCIN C; MYELIN BASIC PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; CELL TRANSFORMATION; CELL TRANSPLANTATION; CONTROLLED STUDY; DENDRITIC CELL; EXPERIMENTAL MODEL; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; MICROARRAY ANALYSIS; MONOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PHENOTYPE; PRIORITY JOURNAL; RAT; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN-PRESENTING CELLS; APOPTOSIS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DENDRITIC CELLS; GRAFT REJECTION; HUMANS; MITOMYCIN; MODELS, IMMUNOLOGICAL; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 67449161554     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.04.024     Document Type: Review

References (75)

1. Billingham R.E., Brent L., and Medawar P.B. Actively acquired tolerance of foreign cells. Nature 172 (1953) 603-606
2. Opelz G., and Terasaki P.I. Poor kidney-transplant survival in recipients with frozen-blood transfusions or no transfusions. Lancet 2 (1974) 696-698
3. Salvatierra Jr. O., Vincenti F., Amend W., Potter D., Iwaki Y., Opelz G., et al. Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg 192 (1980) 543-552
4. Medawar P.B. The behaviour and fate of skin autografts and skin homografts in rabbits: a report to the War Wounds Committee of the Medical Research Council. J Anat 78 (1944) 176-199
5. Golshayan D., Buhler L., Lechler R.I., and Pascual M. From current immunosuppressive strategies to clinical tolerance of allografts. Transpl Int 20 (2007) 12-24
6. Ildstad S.T., and Sachs D.H. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 307 (1984) 168-170
7. Manilay J.O., Pearson D.A., Sergio J.J., Swenson K.G., and Sykes M. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation 66 (1998) 96-102
8. Wekerle T., Kurtz J., Ito H., Ronquillo J.V., Dong V., Zhao G., et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 6 (2000) 464-469
9. Wekerle T., Sayegh M.H., Hill J., Zhao Y., Chandraker A., Swenson K.G., et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 187 (1998) 2037-2044
10. Adams A.B., Durham M.M., Kean L., Shirasugi N., Ha J., Williams M.A., et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 167 (2001) 1103-1111
11. Myburgh J.A., Smit J.A., Mieny C.J., and Mason J.A. Hepatic allotransplantation in the baboon. 3. The effects of immunosuppression and administration of donor-specific antigen after transplantation. Transplantation 12 (1971) 202-210
12. Wood K.J., Ushigome H., Karim M., Bushell A., Hori S., and Sakaguchi S. Regulatory cells in transplantation. Novartis Found Symp 252 (2003) 177-188 discussion 88-93, 203-10
13. Akl A., Luo S., and Wood K.J. Induction of transplantation tolerance-the potential of regulatory T cells. Transpl Immunol 14 (2005) 225-230
14. Xia G., Shah M., and Luo X. Prevention of allograft rejection by amplification of Foxp3(+)CD4(+)CD25(+) regulatory T cells. Transpl Res 153 (2009) 60-70
15. Gregori S., Bacchetta R., Passerini L., Levings M.K., and Roncarolo M.G. Isolation, expansion, and characterization of human natural and adaptive regulatory T cells. Methods Mol Biol 380 (2007) 83-105
16. Barry F.P., Murphy J.M., English K., and Mahon B.P. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev 14 (2005) 252-265
17. Lee K.D. Applications of mesenchymal stem cells: an updated review. Chang Gung Med J 31 (2008) 228-236
18. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003) 685-711
19. Rutella S., Danese S., and Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108 (2006) 1435-1440
20. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
21. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13 (2007) 54-61
22. Jiga L.P., Bauer T.M., Chuang J.J., Opelz G., and Terness P. Generation of tolerogenic dendritic cells by treatment with mitomycin C: inhibition of allogeneic T-cell response is mediated by downregulation of ICAM-1, CD80, and CD86. Transplantation 77 (2004) 1761-1764
23. Jiga L.P., Ehser S., Kleist C., Opelz G., and Terness P. Inhibition of heart allograft rejection with mitomycin C-treated donor dendritic cells. Transplantation 83 (2007) 347-350
24. Li B., Koide Y., Uchijima M., Ohtawara Y., and Fujita K. Pretreatment of recipients with mitomycin-C-treated dendritic cells induces significant prolongation of cardiac allograft survival in mice. Transplant Proc 34 (2002) 3426-3428
25. Yamaguchi Y., Harland R., Wyble C., Mori K., and Bollinger R.R. Variable allograft responses to pretreatment with donor splenocytes treated with mitomycin C in the rat. Transplantation 47 (1989) 360-363
26. Tanigawa T., Monden M., Gotoh M., Nagano H., Hasuike Y., Fukuzaki T., et al. Pretreatment of recipients with mitomycin-C-treated spleen cells induces significant prolongation of cardiac allograft survival in rats. Transplant Proc 26 (1994) 3359-3360
27. Tanigawa T., Gotoh M., Nagano H., Ota H., Fukuzaki T., Sakon M., et al. Injection of mitomycin-C-treated spleen cells induces donor-specific unresponsiveness to cardiac allografts in rats. Transplantation 67 (1999) 653-658
28. Grochowiecki T., Gotoh M., Dono K., Takeda Y., Sakon M., Yagita H., et al. Induction of unresponsiveness to islet xenograft by MMC treatment of graft and blockage of LFA-1/ICAM-1 pathway. Transplantation 69 (2000) 1567-1571
29. Grtochowiecki T., Gotoh M., Dono K., Takeda Y., Nishihara M., Ohta Y., et al. Pretreatment of crude pancreatic islets with mitomycin C prolongs graft survival time in xenogeneic rat-to-mouse model. Transplantation 67 (1999) 1474-1477
30. Wang D., Kleist C., Ehser S., Opelz G., and Terness P. Ex vivo perfusion with mitomycin C containing solution prolongs heart graft survival in rats. Transplantation 82 (2006) 1537-1540
31. Huang Y.M., Yang J.S., Xu L.Y., Link H., and Xiao B.G. Autoantigen-pulsed dendritic cells induce tolerance to experimental allergic encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol 122 (2000) 437-444
32. Zhang G.X., Kishi M., Xu H., and Rostami A. Mature bone marrow-derived dendritic cells polarize Th2 response and suppress experimental autoimmune encephalomyelitis. Mult Scler 8 (2002) 463-468
33. Xiao B.G., Wu X.C., Yang J.S., Xu L.Y., Liu X., Huang Y.M., et al. Therapeutic potential of IFN-gamma-modified dendritic cells in acute and chronic experimental allergic encephalomyelitis. Int Immunol 16 (2004) 13-22
34. Menges M., Rossner S., Voigtlander C., Schindler H., Kukutsch N.A., Bogdan C., et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 195 (2002) 15-21
35. Iruretagoyena M.I., Sepulveda S.E., Lezana J.P., Hermoso M., Bronfman M., Gutierrez M.A., et al. Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 318 (2006) 59-67
36. Li Y., Chu N., Rostami A., and Zhang G.X. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J Immunol 177 (2006) 1679-1688
37. Hirata S., Senju S., Matsuyoshi H., Fukuma D., Uemura Y., and Nishimura Y. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J Immunol 174 (2005) 1888-1897
38. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 (2005) 296-306
39. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85 (1996) 299-302
40. Terness P., Oelert T., Ehser S., Chuang J.J., Lahdou I., Kleist C., et al. Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseases. Proc Natl Acad Sci USA 105 (2008) 18442-18447
41. Verweij J., and Pinedo H.M. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1 (1990) 5-13
42. Liu Z.G., Baskaran R., Lea-Chou E.T., Wood L.D., Chen Y., Karin M., et al. Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 384 (1996) 273-276
43. Chang C.C., Ciubotariu R., Manavalan J.S., Yuan J., Colovai A.I., Piazza F., et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3 (2002) 237-243
44. Cohen N., Mouly E., Hamdi H., Maillot M.C., Pallardy M., Godot V., et al. GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood 107 (2006) 2037-2044
45. Gonzalez-Rey E., Chorny A., O'Valle F., and Delgado M. Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells. Am J Pathol 170 (2007) 263-271
46. Gonzalez-Rey E., Chorny A., Varela N., Robledo G., and Delgado M. Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response. Am J Pathol 168 (2006) 1921-1930
47. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., and Delgado M. Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut 55 (2006) 824-832
48. Bakri Y., Sarrazin S., Mayer U.P., Tillmanns S., Nerlov C., Boned A., et al. Balance of MafB and PU.1 specifies alternative macrophage or dendritic cell fate. Blood 105 (2005) 2707-2716
49. Collins C.S., Hong J., Sapinoso L., Zhou Y., Liu Z., Micklash K., et al. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci USA 103 (2006) 3775-3780
50. Crosier K.E., Wong G.G., Mathey-Prevot B., Nathan D.G., and Sieff C.A. A functional isoform of the human granulocyte/macrophage colony-stimulating factor receptor has an unusual cytoplasmic domain. Proc Natl Acad Sci USA 88 (1991) 7744-7748
51. Nishida K., Yoshida Y., Itoh M., Fukada T., Ohtani T., Shirogane T., et al. Gab-family adapter proteins act downstream of cytokine and growth factor receptors and T- and B-cell antigen receptors. Blood 93 (1999) 1809-1816
52. Yao Z., Zhou G., Wang X.S., Brown A., Diener K., Gan H., et al. A novel human STE20-related protein kinase, HGK, that specifically activates the c-Jun N-terminal kinase signaling pathway. J Biol Chem 274 (1999) 2118-2125
53. Bellamy C.O., Malcomson R.D., Harrison D.J., and Wyllie A.H. Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol 6 (1995) 3-16
54. Liu K., Iyoda T., Saternus M., Kimura Y., Inaba K., and Steinman R.M. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 196 (2002) 1091-1097
55. Hou W.S., and Van Parijs L. A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat Immunol 5 (2004) 583-589
56. Hugues S., Fetler L., Bonifaz L., Helft J., Amblard F., and Amigorena S. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol 5 (2004) 1235-1242
57. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., and Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191 (2000) 423-434
58. Igney F.H., and Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2 (2002) 277-288
59. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
60. Hamdi H., Godot V., Maillot M.C., Prejean M.V., Cohen N., Krzysiek R., et al. Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood 110 (2007) 211-219
61. Berrebi D., Bruscoli S., Cohen N., Foussat A., Migliorati G., Bouchet-Delbos L., et al. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 101 (2003) 729-738
62. Andre P., Biassoni R., Colonna M., Cosman D., Lanier L.L., Long E.O., et al. New nomenclature for MHC receptors. Nat Immunol 2 (2001) 661
63. Vlad G., Cortesini R., and Suciu-Foca N. CD8+ T suppressor cells and the ILT3 master switch. Hum Immunol 69 (2008) 681-686
64. Brown D., Trowsdale J., and Allen R. The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens 64 (2004) 215-225
65. Cella M., Dohring C., Samaridis J., Dessing M., Brockhaus M., Lanzavecchia A., et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 185 (1997) 1743-1751
66. Colonna M., Nakajima H., and Cella M. A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Semin Immunol 12 (2000) 121-127
67. Ravetch J.V., and Lanier L.L. Immune inhibitory receptors. Science 290 (2000) 84-89
68. Vlad G., Cortesini R., and Suciu-Foca N. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J Immunol 174 (2005) 5907-5914
69. Manavalan J.S., Rossi P.C., Vlad G., Piazza F., Yarilina A., Cortesini R., et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 11 (2003) 245-258
70. Liang S., Baibakov B., and Horuzsko A. HLA-G inhibits the functions of murine dendritic cells via the PIR-B immune inhibitory receptor. Eur J Immunol 32 (2002) 2418-2426
71. Maeda A., Scharenberg A.M., Tsukada S., Bolen J.B., Kinet J.P., and Kurosaki T. Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1. Oncogene 18 (1999) 2291-2297
72. Liu J., Liu Z., Witkowski P., Vlad G., Manavalan J.S., Scotto L., et al. Rat CD8+ FOXP3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection. Transpl Immunol 13 (2004) 239-247
73. Steinman L. Immune therapy for autoimmune diseases. Science 305 (2004) 212-216
74. Vandenbark A.A., Vainiene M., Ariail K., Miller S.D., and Offner H. Prevention and treatment of relapsing autoimmune encephalomyelitis with myelin peptide-coupled splenocytes. J Neurosci Res 45 (1996) 430-438
75. Smith C.E., and Miller S.D. Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities. J Autoimmun 27 (2006) 218-231